Aptevo Therapeutics(APVO)
SEATTLE, WABiotechnology
Focus: Aptevo Therapeutics is a Seattle-based public biotech focused on oncology and hematology therapeutics, with a proprietary bispecific antibody platform. The company is in early-stage development with no marketed products and minimal cash reserves.
Profile data last refreshed 16m ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Aptevo Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Aptevo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Aptevo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ES414
Prostate CancerClinical Trials (1)
NCT02262910Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
Phase 1Help build intelligence for Aptevo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.